TLR7 and neoplasm: MEDI9197 (3M-052), a novel designed lipophilic TLR7/8 agonist, is found to regulate the enrichment and activation of CD8+ T cells and NK cells, polarization of Th1 cells and inhibition of tumor growth in multiple syngeneic models [113].